Loading…
← CockpitCompetitor Analysis › 300497.SZ Jiangxi Fushine Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Jiangxi Fushine Pharmaceutical Co., Ltd. Class A300497.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.

Momentum weak 34
Mkt cap
$1.02B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$42.6M
20-day average traded
Fwd P/E
9.9×
forward earnings
ROIC−WACC
+4.2 pp
WACC 8.3%
Hurdle
+12 pp
Req g minus delivered
Next earnings
166 days
3 May 2027
Close · CNYCN¥13.02
1D-1.4%
1W-8.9%
1M-9.7%
3M-28.7%
6M-23.1%
YTD-13.8%
1Y+22.5%
ATR %5.5%
52w lowhigh46.1% off high

What Jiangxi Fushine Pharmaceutical does

Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics

Moat: none

Headquarters: Jiangxi, China · Employees: 1,663

Jiangxi Fushine Pharmaceutical at a glance

Size Jiangxi Fushine Pharmaceutical (300497.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.02B, the 2118th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.02 on 18 Nov 2026.

Performance Over six months the shares fell 23.1%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 102.6% over the last twelve months (peer median +5.9%); the operating margin is 24.0% (peer median 8.7%).

Valuation It trades at 9.9× forward earnings against a peer median of 20.6× (3rd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.2 points above its cost of capital (8.3% WACC).

Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 92300497.SZ 79
Six months, rebased to 100: Jiangxi Fushine Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangxi Fushine Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.97BCN¥1.18BCN¥1.17BCN¥1.61BCN¥1.64B
Revenue growth—+1%-27%-2%—
Gross profitCN¥905MCN¥151MCN¥19.9MCN¥108MCN¥244M
EBITDAn/aCN¥146M-CN¥22.0M-CN¥16.3MCN¥60.0M
Net incomeCN¥411M-CN¥55.0M-CN¥272M-CN¥201M-CN¥141M
Free cash flowCN¥60.0M-CN¥161MCN¥46.9M-CN¥306M-CN¥579M
Capital expenditureCN¥142MCN¥225MCN¥142MCN¥242MCN¥459M
Total debtCN¥1.63BCN¥1.75BCN¥1.95BCN¥1.98BCN¥1.79B

Quarterly statements and history in the cockpit →

Jiangxi Fushine Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%68851330070245530006500027374887SVRABSLN600789688091605116688710BLUEJET1952AARTIPHARM688382600129SPTXPGHL300497.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangxi Fushine Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×20×40×60×68851330070245530006500027374887BSLN688710BLUEJET1952600129300497.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangxi Fushine Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%6885133007024553000650002737BSLN605116688710BLUEJET688382300497.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangxi Fushine Pharmaceutical is the large dot.

Jiangxi Fushine Pharmaceutical competitors and peer comparison

How Jiangxi Fushine Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangxi Fushine Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300497.SZPeer medianRank in peer set
1-month return-9.7%-5.0%9th lowest of 21
6-month return-23.1%-10.6%4th lowest of 21
Distance from 52-week high-46.1%-32.1%6th lowest of 21
Revenue growth (TTM)+102.6%+5.9%2nd highest of 19
Operating margin24.0%8.7%4th highest of 19
Forward P/E9.9×20.6×3rd cheapest of 15
Growth the price implies (Req g, 7 yrs)7.5%2.5%3rd most demanding of 14
Growth delivered (Del g)-4.5%+7.7%4th lowest of 14
Hurdle (Req g minus delivered)+12.0 pp-3.6 pp3rd most demanding of 14
ROIC minus cost of capital+4.2 pp+0.1 pp6th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%

Questions

Which companies are Jiangxi Fushine Pharmaceutical's closest peers?
The cockpit's peer set: Chengdu Easton Biopharmaceuticals (688513.SS), Zhejiang Tianyu Pharmaceutical (300702.SZ), Towa Pharmaceutical (4553.T), Renhe Pharmacy (000650.SZ), Sunflower Pharmaceutical (002737.SZ), SAWAI (4887.T), Savara (SVRA), Basilea Pharmaceutica (BSLN.SW).
Is Jiangxi Fushine Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.9× against a peer median of 20.6×, 3rd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiangxi Fushine Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -23.1% against -10.6% for the median peer; over one year +22.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.